nach oben

Tumor Biology

Erschienen in:

01.01.2010 | Research Article

COX-2 is associated with proliferation and apoptosis markers and serves as an independent prognostic factor in gastric cancer

verfasst von: Johanna Mrena, Jan-Patrik Wiksten, Arto Kokkola, Stig Nordling, Ari Ristimäki, Caj Haglund

Erschienen in: Tumor Biology | Ausgabe 1/2010

Einloggen, um Zugang zu erhalten

Abstract

Cyclooxygenase-2 (COX-2) is an important factor in gastric carcinogenesis, and COX-2 expression in gastric cancer patients correlates with prognosis. We have now studied the impact of COX-2 in comparison to six other tissue tumor markers, DNA index, and S-phase fraction (SPF) in a large series of gastric cancer specimens. From 342 consecutive patients, 337 archival tissue specimens were available for immunohistochemistry of COX-2, HuR, cyclin A, MMP-2, p53, p21, and Ki-67 and 313 for analysis of DNA index and S-phase fraction by flow cytometry. Associations between factors were assessed by chi-square test and survival analysis by the Kaplan–Meier method and Cox model. A significant association emerged between of COX-2 and p53 (p < 0.0001), Ki-67 (p = 0.013), DNA ploidy (p < 0.0001), and SPF (p < 0.0001). In an extended multivariate analysis, COX-2 and p53 expression were independent prognostic factors for poor survival, in addition to high stage and non-curative surgery. In gastric cancer, COX-2 expression associated with markers for apoptosis and proliferation, and furthermore, it was confirmed that COX-2 and p53 are strong prognostic indicators.

Kountouras J, Zavos C, Chatzopoulos D. Apoptotic and anti-angiogenic strategies in liver and gastrointestinal malignancies. J Surg Oncol. 2005;90(4):249–59.CrossRefPubMed

Mann JR, DuBois RN. Cyclooxygenase-2 and gastrointestinal cancer. Cancer J. 2004;10(3):145–52.CrossRefPubMed

Wang D, Dubois RN. Prostaglandins and cancer. Gut. 2006;55(1):115–22.CrossRefPubMed

Oshima H, Oshima M, Inaba K, Taketo MM. Hyperplastic gastric tumors induced by activated macrophages in COX-2/mPGES-1 transgenic mice. EMBO J. 2004;23:1669–78.CrossRefPubMed

Saukkonen K, Tomasetto C, Narko K, Rio MC, Ristimaki A. Cyclooxygenase-2 expression and effect of celecoxib in gastric adenomas of trefoil factor 1-deficient mice. Cancer Res. 2003;63(12):3032–6.PubMed

Lim HY, Joo HJ, Choi JH, Yi JW, Yang MS, Cho DY, et al. Increased expression of cyclooxygenase-2 protein in human gastric carcinoma. Clin Cancer Res. 2000;6(2):519–25.PubMed

Saukkonen K, Nieminen O, van Rees B, Vilkki S, Harkonen M, Juhola M, et al. Expression of cyclooxygenase-2 in dysplasia of the stomach and in intestinal-type gastric adenocarcinoma. Clin Cancer Res. 2001;7(7):1923–31.PubMed

van Rees BP, Saukkonen K, Ristimaki A, Polkowski W, Tytgat GN, Drillenburg P, et al. Cyclooxygenase-2 expression during carcinogenesis in the human stomach. J Pathol. 2002;196(2):171–9.CrossRefPubMed

Ristimaki A, Honkanen N, Jankala H, Sipponen P, Harkonen M. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res. 1997;57(7):1276–80.PubMed

10.

Saukkonen K, Rintahaka J, Sivula A, Buskens CJ, Van Rees BP, Rio MC, et al. Cyclooxygenase-2 and gastric carcinogenesis. Apmis. 2003;111(10):915–25.CrossRefPubMed

11.

Li JY, Wang XZ, Chen FL, Yu JP, Luo HS. Nimesulide inhibits proliferation via induction of apoptosis and cell cycle arrest in human gastric adenocarcinoma cell line. World J Gastroenterol. 2003;9(5):915–20.PubMed

12.

Mrena J, Wiksten JP, Thiel A, Kokkola A, Pohjola L, Lundin J, et al. Cyclooxygenase-2 is an independent prognostic factor in gastric cancer and its expression is regulated by the messenger RNA stability factor HuR. Clin Cancer Res. 2005;11(20):7362–8.CrossRefPubMed

13.

Steele RJ, Lane DP. P53 in cancer: a paradigm for modern management of cancer. Surgeon. 2005;3(3):197–205.CrossRefPubMed

14.

Schwartz GK. Development of cell cycle active drugs for the treatment of gastrointestinal cancers: a new approach to cancer therapy. J Clin Oncol. 2005;23(20):4499–508.CrossRefPubMed

15.

Gartel AL, Radhakrishnan SK. Lost in transcription: p21 repression, mechanisms, and consequences. Cancer Res. 2005;65(10):3980–85.CrossRefPubMed

16.

Endl E, Gerdes J. The Ki-67 protein: fascinating forms and an unknown function. Exp Cell Res. 2000;257(2):231–7.CrossRefPubMed

17.

Baba H, Korenaga D, Kakeji Y, Haraguchi M, Okamura T, Maehara Y. DNA ploidy and its clinical implications in gastric cancer. Surgery. 2002;131(1 Suppl):S63–70.CrossRefPubMed

18.

Korenaga D, Okamura T, Saito A, Baba H, Sugimachi K. DNA ploidy is closely linked to tumor invasion, lymph node metastasis, and prognosis in clinical gastric cancer. Cancer. 1988;62(2):309–13.CrossRefPubMed

19.

Victorzon M, Roberts PJ, Haglund C, von Boguslawsky K, Nordling S. Ki-67 immunoreactivity, ploidy and S-phase fraction as prognostic factors in patients with gastric carcinoma. Oncology. 1996;53(3):182–91.CrossRefPubMed

20.

Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 1998;4(7):844–7.CrossRefPubMed

21.

Mrena J, Wiksten JP, Kokkola A, Nordling S, Haglund C, Ristimaki A. Prognostic significance of cyclin A in gastric cancer. Int J Cancer. 2006;119(8):1897–901.CrossRefPubMed

22.

Mrena J, Wiksten JP, Nordling S, Kokkola A, Ristimaki A, Haglund C. MMP-2 but not MMP-9 associated with COX-2 and survival in gastric cancer. J Clin Pathol. 2006;59(6):618–23.CrossRefPubMed

23.

Wiksten JP, Lundin J, Nordling S, Kokkola A, Haglundi C. Comparison of the prognostic value of a panel of tissue tumor markers and established clinicopathological factors in patients with gastric cancer. Anticancer Res. 2008;28(4C):2279–87.PubMed

24.

Yonemura Y, Ooyama S, Sugiyama K, Kamata T, De Aretxabala X, Kimura H, et al. Retrospective analysis of the prognostic significance of DNA ploidy patterns and S-phase fraction in gastric carcinoma. Cancer Res. 1990;50(3):509–14.PubMed

25.

Setala LP, Nordling S, Kosma VM, Lipponen PK, Eskelinen MJ, Hollmen SM, et al. Comparison of DNA ploidy and S-phase fraction with prognostic factors in gastric cancer. Anal Quant Cytol Histol. 1997;19(6):524–32.PubMed

26.

Abad M, Ciudad J, Rincon MR, Silva I, Paz-Bouza JI, Lopez A, et al. DNA aneuploidy by flow cytometry is an independent prognostic factor in gastric cancer. Anal Cell Pathol. 1998;16(4):223–31.PubMed

27.

Russo A, Bazan V, Migliavacca M, Zanna I, Tubiolo C, Tumminello FM, et al. Prognostic significance of DNA ploidy, S-phase fraction, and tissue levels of aspartic, cysteine, and serine proteases in operable gastric carcinoma. Clin Cancer Res. 2000;6(1):178–84.PubMed

28.

Yasa MH, Bektas A, Yukselen V, Akbulut H, Camci C, Ormeci N. DNA analysis and DNA ploidy in gastric cancer and gastric precancerous lesions. Int J Clin Pract. 2005;59(9):1029–33.CrossRefPubMed

29.

Subbaramaiah K, Altorki N, Chung WJ, Mestre JR, Sampat A, Dannenberg AJ. Inhibition of cyclooxygenase-2 gene expression by p53. J Biol Chem. 1999;274(16):10911–5.CrossRefPubMed

30.

Leung WK, To KF, Ng YP, Lee TL, Lau JY, Chan FK, et al. Association between cyclo-oxygenase-2 overexpression and missense p53 mutations in gastric cancer. Br J Cancer. 2001;84(3):335–9.CrossRefPubMed

31.

Shun CT, Wu MS, Huang SP, Wang HP, Chuang SM, Lin JT. Cyclooxygenase-2 expression correlates with nuclear p53 accumulation in gastric carcinoma. Hepatogastroenterology. 2003;50(52):988–92.PubMed

32.

Kawabe A, Shimada Y, Uchida S, Maeda M, Yamasaki S, Kato M, et al. Expression of cyclooxygenase-2 in primary and remnant gastric carcinoma: comparing it with p53 accumulation, Helicobacter pylori infection, and vascular endothelial growth factor expression. J Surg Oncol. 2002;80(2):79–88.CrossRefPubMed

33.

Joo YE, Chung IJ, Park YK, Koh YS, Lee JH, Park CH, et al. Expression of cyclooxygenase-2, p53 and Ki-67 in gastric cancer. J Korean Med Sci. 2006;21(5):871–6.CrossRefPubMed

34.

Xu L, Zhang SM, Wang YP, Zhao FK, Wu DY, Yan X. Relationship between DNA ploidy, expression of ki-67 antigen and gastric cancer metastasis. World J Gastroenterol. 1999;5(1):10–1.PubMed

35.

Kunisaki C, Shimada H, Takahashi M, Ookubo K, Moriwaki Y, Akiyama H, et al. Prognostic factors in early gastric cancer. Hepatogastroenterology. 2001;48(37):294–8.PubMed

36.

Liu XP, Tsushimi K, Tsushimi M, Kawauchi S, Oga A, Furuya T, et al. Expression of p21(WAF1/CIP1) and p53 proteins in gastric carcinoma: its relationships with cell proliferation activity and prognosis. Cancer Lett. 2001;170(2):183–9.CrossRefPubMed

37.

Oshima CT, Iriya K, Forones NM. Ki-67 as a prognostic marker in colorectal cancer but not in gastric cancer. Neoplasma. 2005;52(5):420–4.PubMed

38.

Ochiai H, Nakanishi Y, Fukasawa Y, Sato Y, Yoshimura K, Moriya Y, et al. A new formula for predicting liver metastasis in patients with colorectal cancer: immunohistochemical analysis of a large series of 439 surgically resected cases. Oncology. 2008;75(1-2):32–41.CrossRefPubMed

39.

Kim YJ, Kim MA, Im SA, Kim TM, Kim DW, Yang HK, et al. Metastasis-associated protein S100A4 and p53 predict relapse in curatively resected stage III and IV (M0) gastric cancer. Cancer Invest. 2008;26(2):152–8.CrossRefPubMed

Titel: COX-2 is associated with proliferation and apoptosis markers and serves as an independent prognostic factor in gastric cancer
verfasst von: Johanna Mrena
Jan-Patrik Wiksten
Arto Kokkola
Stig Nordling
Ari Ristimäki
Caj Haglund
Publikationsdatum: 01.01.2010
Verlag: Springer Netherlands
Erschienen in: Tumor Biology / Ausgabe 1/2010
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-009-0001-4

Neu im Fachgebiet Onkologie

18.04.2024 | Wirbelsäulenmetastase | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

COX-2 is associated with proliferation and apoptosis markers and serves as an independent prognostic factor in gastric cancer

Abstract

Neu im Fachgebiet Onkologie

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2010

Pro-apoptotic and antiproliferative activity of human KCNRG, a putative tumor suppressor in 13q14 region

Estrogen prevents sustained COLO-205 human colon cancer cell growth by inducing apoptosis, decreasing c-myb protein, and decreasing transcription of the anti-apoptotic protein bcl-2

The role of Crk/Dock180/Rac1 pathway in the malignant behavior of human ovarian cancer cell SKOV3

Laminin-derived peptide AG73 regulates migration, invasion, and protease activity of human oral squamous cell carcinoma cells through syndecan-1 and β1 integrin

MTHFR polymorphisms in gastric cancer and in first-degree relatives of patients with gastric cancer

Clinicopathologic prognostic markers of survival: an analysis of 259 patients with malignant melanoma ≥1 mm

Neu im Fachgebiet Onkologie

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Update Onkologie